Supplementary Figure S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Key Points

MAIN FINDING: The study demonstrates that toripalimab serves as a promising second-line therapy for advanced hepatocellular carcinoma.
KEY EVIDENCE: Efficacy was analyzed in correlation to the tumor immune microenvironment, indicating significant therapeutic potential.
APPROACH: The multicenter and open-label design involved various participants to comprehensively assess treatment outcomes.
SIGNIFICANCE: These results could lead to improved treatment options for patients with advanced hepatocellular carcinoma in clinical practice.

Phase I study shows toripalimab improves efficacy in advanced hepatocellular carcinoma, suggesting potential for second-line therapy.

Supplementary Figure S3. Exploration of the association between the tumor immune microenvironment and efficacy.

No takes yet. Share an insight, caveat, or question.

Zhang et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share